Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $159.95 +1.23%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.50), $0.43 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $500.92 million versus the consensus estimate of $532.36 million.
The company reiterated 2024 financial guidance, including combined Net Product revenues of $1,575 million to $1,650 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades PayPal (PYPL) to Hold
- Canaccord Downgrades Driven Brands (DRVN) to Hold
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
